Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 61.00 | |
5 mg | In stock | $ 148.00 | |
10 mg | In stock | $ 253.00 | |
25 mg | In stock | $ 497.00 | |
50 mg | In stock | $ 743.00 | |
100 mg | In stock | $ 1,050.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 97.00 |
Description | MDR-1339 is a blood-brain-barrier-permeable inhibitor of amyloid-β (Aβ) aggregation. |
In vitro | MDR-1339 shows no significant inhibition of a panel of CYP isozymes, while it slightly inhibits CYP2C8 (IC50: 31.4 μM). MDR-1339 (1.5-10 μM) protects cells from this Aβ-induced toxicity. MDR-1339 (3.1-50 μM) also dose-dependently blocks the formation of Aβ aggregates and disaggregates Aβ fibrils. |
In vivo | MDR-1339 (0.1-10 mg/kg, p.o.) dose-dependently restores the passive avoidance responses in mice models of Alzheimer's disease (ED50: 0.19 mg/kg). MDR-1339 (30 and 100 mg/kg, p.o. daily for 8 weeks) significantly improves spontaneous alternation and reduces the Aβ1-40 and Aβ1-42 levels in APP/PS1 mice. |
Synonyms | DWK-1339 |
Molecular Weight | 326.39 |
Formula | C20H22O4 |
CAS No. | 1018946-38-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (245.11 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MDR-1339 1018946-38-7 Neuroscience Proteases/Proteasome Stem Cells Beta Amyloid Gamma-secretase inhibit DWK-1339 β-amyloid peptide Inhibitor DWK1339 MDR 1339 Abeta Amyloid-β MDR1339 DWK 1339 inhibitor